Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

GLP-1 drugs like Ozempic® and Zepbound®, have gained significant attention in recent years for treating both diabetes and ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

The Saudi Arabia diabetes market reached a value of USD 373.4 million in 2024 and is projected to grow to USD 494.4 million by 2033, exhibiting a steady compound annual growth rate (CAGR) of 3.17% ...

Indian pharma speeds up access to global therapies while targeting treatment gaps: Nandita Vijayasimha, Bengaluru Saturday, June 28, 2025, 08:00 Hrs [IST] Indian pharma is now agg ...

Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane ...

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

In this retrospective cohort study, treatment with semaglutide resulted in nominally lower incidence of the composite of death, myocardial infarction, and stroke compared to empagliflozin in patients ...

There is also potential to reduce the dose of GLP-1 agonists with add-on inflammasome inhibitor treatment to help alleviate GI side effects and thus improve duration of anti-obesity therapy.

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update ...

DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of ...